Latest progress from PharmNovo at EFIC
PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.
“We are very much looking forward to the congress and to describe our latest progress. PharmNovo is at the forefront of the field, pioneering the development of a delta opioid agonist. At this stage, we are more than ready to present our successful outcomes to the meeting, and to share these with our peers, investors, and collaborators”, says PharmNovo's Founder and Scientific Advisor, Bengt von Mentzer.
Bengt von Mentzer will be presenting two posters on PharmNovo's PN6047, our innovative drug candidate for neuropathic pain:
- Toxicity and safety testing of PN6047 – a delta agonist
In preclinical studies, PN6047 is shown to be safe and well tolerated with a wide estimated therapeutic window and lacking abuse potential. Preliminary results from the human phase I study show a similar profile and strongly indicate that PN6047 will be safe and tolerable and able to enter phase II efficacy studies in neuropathic pain patients.
- Antitussive activity of delta opioid receptor agonists
New data indicate that delta opioid agonists could provide a potential novel therapy for chronic cough without the unwanted effects, such as reduced respiration, of conventional non-selective opioids.
“Our successful phase I study was executed with professionalism and speed. We have now passed several important milestones and are well on our way in our mission to launch PN6047 as a compound for treating neuropathic pain and other conditions involving hypersensitivity in the nervous system. We are excited to enter the next, phase 2, stage of clinical testing with the potential of providing a new therapy to the millions of people suffering from neuropathic pain” says Bengt von Mentzer.
The European Pain Federation EFIC is a non-profit organisation representing healthcare professionals in pain management and science.
To learn more about the Congress of the European Pain Federation and to explore the agenda for the world congress, visit: https://europeanpainfederation.eu/efic2023/
Latest progress from PharmNovo at EFIC
PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.
“We are very much looking forward to the congress and to describe our latest progress. PharmNovo is at the forefront of the field, pioneering the development of a delta opioid agonist. At this stage, we are more than ready to present our successful outcomes to the meeting, and to share these with our peers, investors, and collaborators”, says PharmNovo's Founder and Scientific Advisor, Bengt von Mentzer.
Bengt von Mentzer will be presenting two posters on PharmNovo's PN6047, our innovative drug candidate for neuropathic pain:
- Toxicity and safety testing of PN6047 – a delta agonist
In preclinical studies, PN6047 is shown to be safe and well tolerated with a wide estimated therapeutic window and lacking abuse potential. Preliminary results from the human phase I study show a similar profile and strongly indicate that PN6047 will be safe and tolerable and able to enter phase II efficacy studies in neuropathic pain patients.
- Antitussive activity of delta opioid receptor agonists
New data indicate that delta opioid agonists could provide a potential novel therapy for chronic cough without the unwanted effects, such as reduced respiration, of conventional non-selective opioids.
“Our successful phase I study was executed with professionalism and speed. We have now passed several important milestones and are well on our way in our mission to launch PN6047 as a compound for treating neuropathic pain and other conditions involving hypersensitivity in the nervous system. We are excited to enter the next, phase 2, stage of clinical testing with the potential of providing a new therapy to the millions of people suffering from neuropathic pain” says Bengt von Mentzer.
The European Pain Federation EFIC is a non-profit organisation representing healthcare professionals in pain management and science.
To learn more about the Congress of the European Pain Federation and to explore the agenda for the world congress, visit: https://europeanpainfederation.eu/efic2023/
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
